Interaction Checker

Interaksi Eksemestan

Eksemestan (Aromasin), golongan penghambat aromatase, memiliki 61 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 16 mayor, 33 moderat, 12 minor, dan 0 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi mayor (16)

  • Desogestrel dan etinilestradiolkontrasepsi oralMayor

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (label Eksemestan, Peringatan dan perhatian)

  • Drospirenon dan etinilestradiolkontrasepsi oralMayor

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (label Eksemestan, Peringatan dan perhatian)

  • EstradiolestrogenMayor

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (label Eksemestan, Peringatan dan perhatian)

  • Estradiol dan dienogestkontrasepsi oralMayor

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (label Eksemestan, Peringatan dan perhatian)

  • Estradiol dan noretisteronestrogenMayor

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (label Eksemestan, Peringatan dan perhatian)

  • Estrogen teresterifikasi dan metiltestosteronestrogenMayor

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (label Eksemestan, Peringatan dan perhatian)

  • Estrogen terkonjugasiestrogenMayor

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (label Eksemestan, Peringatan dan perhatian)

  • Estrogen terkonjugasi dan bazedoksifenestrogenMayor

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (label Eksemestan, Peringatan dan perhatian)

  • Etinodiol diasetat dan etinilestradiolkontrasepsi oralMayor

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (label Eksemestan, Peringatan dan perhatian)

  • Etonogestrel dan etinilestradiolestrogenMayor

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (label Eksemestan, Peringatan dan perhatian)

  • FulvestrantestrogenMayor

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (label Eksemestan, Peringatan dan perhatian)

  • Levonorgestrel dan etinilestradiolkontrasepsi oralMayor

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (label Eksemestan, Peringatan dan perhatian)

  • Norelgestromin dan etinilestradiolestrogenMayor

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (label Eksemestan, Peringatan dan perhatian)

  • Noretisteron dan etinilestradiolkontrasepsi oralMayor

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (label Eksemestan, Peringatan dan perhatian)

  • Norgestimat dan etinilestradiolkontrasepsi oralMayor

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (label Eksemestan, Peringatan dan perhatian)

  • Norgestrel dan etinilestradiolkontrasepsi oralMayor

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (label Eksemestan, Peringatan dan perhatian)

Interaksi moderat (33)

  • Aprepitantpenghambat CYP3A4Moderat

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (label Eksemestan, Interaksi obat)

  • Armodafinilstimulan SSPModerat

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (label Eksemestan, Interaksi obat)

  • Bosentanpenginduksi CYP3A4Moderat

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (label Eksemestan, Interaksi obat)

  • Deferasirokssuplemen zat besiModerat

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (label Eksemestan, Interaksi obat)

  • DeksametasonkortikosteroidModerat

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (label Eksemestan, Interaksi obat)

  • EfavirenzantiretroviralModerat

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (label Eksemestan, Interaksi obat)

  • Efavirenz, lamivudin, dan tenofovirantiretroviralModerat

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (label Eksemestan, Interaksi obat)

  • EslikarbazepinantikonvulsanModerat

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (label Eksemestan, Interaksi obat)

  • EtravirinantiretroviralModerat

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (label Eksemestan, Interaksi obat)

  • FenitoinantikonvulsanModerat

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (label Eksemestan, Interaksi obat)

  • FenobarbitalbarbituratModerat

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (label Eksemestan, Interaksi obat)

  • Fentermin dan topiramatstimulan SSPModerat

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (label Eksemestan, Interaksi obat)

  • FosfenitoinantikonvulsanModerat

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (label Eksemestan, Interaksi obat)

  • GriseofulvinantijamurModerat

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (label Eksemestan, Interaksi obat)

  • KarbamazepinantikonvulsanModerat

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (label Eksemestan, Interaksi obat)

  • KlobazambenzodiazepinModerat

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (label Eksemestan, Interaksi obat)

  • Lopinavir dan ritonavirantiretroviralModerat

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (label Eksemestan, Interaksi obat)

  • Lorlatinibpenginduksi CYP3A4Moderat

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (label Eksemestan, Interaksi obat)

  • Mitapivatpenginduksi CYP3A4Moderat

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (label Eksemestan, Interaksi obat)

  • Mitotanpenginduksi CYP3A4Moderat

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (label Eksemestan, Interaksi obat)

  • Modafinilstimulan SSPModerat

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (label Eksemestan, Interaksi obat)

  • Nafsilinantibiotik penisilinModerat

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (label Eksemestan, Interaksi obat)

  • NevirapinantiretroviralModerat

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (label Eksemestan, Interaksi obat)

  • OkskarbazepinantikonvulsanModerat

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (label Eksemestan, Interaksi obat)

  • PrimidonantikonvulsanModerat

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (label Eksemestan, Interaksi obat)

  • RifabutinantibiotikModerat

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (label Eksemestan, Interaksi obat)

  • RifampisinantibiotikModerat

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (label Eksemestan, Interaksi obat)

  • RifapentinantibiotikModerat

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (label Eksemestan, Interaksi obat)

  • RitonavirantiretroviralModerat

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (label Eksemestan, Interaksi obat)

  • SenobamatantikonvulsanModerat

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (label Eksemestan, Interaksi obat)

  • Suzetriginpenginduksi CYP3A4Moderat

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (label Eksemestan, Interaksi obat)

  • Tamoksifenmodulator reseptor estrogen selektifModerat

    Percent Change in BMD from Baseline to 24 months, Exemestane vs. Control 1 IES 027 BMD Exemestane N=29 Tamoxifen 1 N=38 Exemestane N=59 Placebo 1 N=65 Lumbar spine (%) -3.1 -0.2 -3.5 -2.4 Femoral neck (%) -4.2 -0.3 -4.6 -2.6 During adjuvant treatment with exemestane, women with osteoporosis or at risk of osteoporosis should have their bone mineral density formally… (label Eksemestan, Peringatan dan perhatian)

  • TopiramatantikonvulsanModerat

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (label Eksemestan, Interaksi obat)

Penyebutan minor (12)

  • AlendronatbisfosfonatMinor

    Concomitant use of bisphosphonates, vitamin D supplementation, and calcium was not allowed. (label Eksemestan, Peringatan dan perhatian)

  • Asam zoledronatbisfosfonatMinor

    Concomitant use of bisphosphonates, vitamin D supplementation, and calcium was not allowed. (label Eksemestan, Peringatan dan perhatian)

  • Dokserkalsiferolanalog vitamin DMinor

    • Routine assessment of 25-hydroxy vitamin D levels prior to the start of aromatase inhibitor treatment should be performed ( 5.2 ). (label Eksemestan, Peringatan dan perhatian)

  • Fenobarbital, hiosiamin, atropin, dan skopolaminbarbituratMinor

    Drugs That Induce CYP 3A4 Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. (label Eksemestan, Interaksi obat)

  • IbandronatbisfosfonatMinor

    Concomitant use of bisphosphonates, vitamin D supplementation, and calcium was not allowed. (label Eksemestan, Peringatan dan perhatian)

  • Kalsipotriolanalog vitamin DMinor

    • Routine assessment of 25-hydroxy vitamin D levels prior to the start of aromatase inhibitor treatment should be performed ( 5.2 ). (label Eksemestan, Peringatan dan perhatian)

  • Kalsitriolanalog vitamin DMinor

    • Routine assessment of 25-hydroxy vitamin D levels prior to the start of aromatase inhibitor treatment should be performed ( 5.2 ). (label Eksemestan, Peringatan dan perhatian)

  • MegestrolprogestinMinor

    In the comparative study in advanced breast cancer patients, CTC grade 3 or 4 elevation of gamma glutamyl transferase without documented evidence of liver metastasis was reported in 2.7% of patients treated with EXEMESTANE and in 1.8% of patients treated with megestrol acetate. (label Eksemestan, Peringatan dan perhatian)

  • PamidronatbisfosfonatMinor

    Concomitant use of bisphosphonates, vitamin D supplementation, and calcium was not allowed. (label Eksemestan, Peringatan dan perhatian)

  • Parikalsitolanalog vitamin DMinor

    • Routine assessment of 25-hydroxy vitamin D levels prior to the start of aromatase inhibitor treatment should be performed ( 5.2 ). (label Eksemestan, Peringatan dan perhatian)

  • RisedronatbisfosfonatMinor

    Concomitant use of bisphosphonates, vitamin D supplementation, and calcium was not allowed. (label Eksemestan, Peringatan dan perhatian)

  • Vitamin DVitamin dan mineralMinor

    • Routine assessment of 25-hydroxy vitamin D levels prior to the start of aromatase inhibitor treatment should be performed ( 5.2 ). (label Eksemestan, Peringatan dan perhatian)

Periksa Eksemestan terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.